



2018-08-24

Magnesium EQL Pharma

The drug Magnesium EQL Pharma has today been approved for sale by the Swedish Medicines Agency.

Magnesium EQL Pharma is used in diagnosed or suspected magnesium deficiency as well as prophylaxis in idiopathic recurrent renal disease.

The drug Magnesium EQL Pharma is a pronounced niche generic where EQL Pharma becomes the only, and first, generic on the Swedish market for more than 35 years. The product is medium sized with approximately 8 MSEK in total annual sales in the Swedish market.

The product is expected to be launched around the year 2018/2019.

For further information, please contact:

Christer Fåhraeus

CEO EQL Pharma AB (publ)

Phone: +46 (0) 705 – 60 90 00

E-mail: christer.fahraeus@eqlpharma.com

Website: www.eqlpharma.com

About EQL Pharma

EQL Pharma is specialized in developing and selling generics, i.e. drugs that are medically equivalent to the original medicines. The company currently markets nine (9) generics in the Swedish, Danish and Finnish markets. In addition to these, there is a significant pipeline of additional niche generics (generics with little or no competition except for the original) for launch in 2018 and onwards. The business is currently entirely focused on prescription pharmaceuticals in the Nordic region. EQL Pharma is based in Lund, Sweden, employs 7 (7) people and is listed on Spotlight Stock Market (AktieTorget). EQL Pharma also conducts extensive development in cooperation with leading contract manufacturers developers and major pharmaceutical companies in, amongst other countries, India and China.